CENTERS FOR THE DEVELOPMENT OF MEDICATIONS TO TREAT DRUG AND DRUG ADDICTION -
ADDENDUM
Release Date: October 8, 1998
RFA: DA-99-005
P.T.
National Institute on Drug Abuse
In response to applicant inquiries, the National Institute on Drug Abuse (NIDA)
is clarifying what is meant by multisite projects for RFA DA-99-005, published
in the NIH Guide for Contracts and Grants, September 16, 1998:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-99-005.html.
In order to be considered for multisite designation under the RFA (and therefore
to allow budget to exceed $1,000,000), proposed trials will be expected to meet
the following points:
o consist of a minimum of three separate sites
o be geographically diverse - not located in the same city or generally in the
same state
o be characterized by diverse subject populations across sites
o have separate and independent staffing at the different sites
o demonstrate power estimates that defend sample size estimates and document
recruitment history at sites identified such that recruitment within an
appropriate time frame (less than 2 years) could occur
o estimation of power must be based on observational data, not from
theoretically based assumptions and analyses - empirically based sample estimates
will not be considered sufficient.
o provide a strong justification for the advantage of a multisite trial at the
particular point of development of the compound in question
o clearly indicate that funding above the $1.0M cap will be for costs associated
with additional sites - not applicant site
INQUIRIES
Inquiries concerning this notice may be directed to:
Barbara Herman, Ph.D.
Medications Development Division
National Institute on Drug Abuse
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-3318/9799
FAX: (301) 443-2599
Email: [email protected]
Return to NIH Guide Main Index
|
Office of Extramural Research (OER) |
|
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
|
Department of Health and Human Services (HHS) |
|
||||